Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lipoproteins | 6 | 2023 | 871 | 1.640 |
Why?
|
Triglycerides | 7 | 2023 | 2441 | 1.610 |
Why?
|
Benzoxazoles | 2 | 2024 | 92 | 1.440 |
Why?
|
Peripheral Arterial Disease | 7 | 2023 | 1304 | 1.260 |
Why?
|
Cardiovascular Diseases | 25 | 2024 | 15657 | 1.100 |
Why?
|
C-Reactive Protein | 18 | 2023 | 3853 | 0.980 |
Why?
|
Diabetes Mellitus, Type 2 | 25 | 2024 | 12245 | 0.950 |
Why?
|
Gangrene | 1 | 2024 | 92 | 0.910 |
Why?
|
Cholesterol, LDL | 6 | 2020 | 2392 | 0.850 |
Why?
|
Butyrates | 2 | 2024 | 164 | 0.800 |
Why?
|
Hyperhomocysteinemia | 1 | 2021 | 117 | 0.710 |
Why?
|
Diabetic Foot | 1 | 2024 | 383 | 0.690 |
Why?
|
Peripheral Vascular Diseases | 3 | 2009 | 488 | 0.670 |
Why?
|
Hypertriglyceridemia | 2 | 2021 | 292 | 0.660 |
Why?
|
Ankle Brachial Index | 1 | 2020 | 163 | 0.650 |
Why?
|
Homocysteine | 3 | 2021 | 638 | 0.640 |
Why?
|
Natriuretic Peptide, Brain | 4 | 2017 | 1750 | 0.640 |
Why?
|
Intercellular Adhesion Molecule-1 | 6 | 2020 | 1131 | 0.620 |
Why?
|
Serine Proteinase Inhibitors | 1 | 2018 | 174 | 0.540 |
Why?
|
Amino Acid Metabolism, Inborn Errors | 1 | 2018 | 283 | 0.500 |
Why?
|
Peptide Fragments | 4 | 2017 | 5143 | 0.490 |
Why?
|
Hypolipidemic Agents | 1 | 2019 | 609 | 0.460 |
Why?
|
Troponin T | 3 | 2017 | 786 | 0.450 |
Why?
|
Incidence | 20 | 2024 | 21525 | 0.450 |
Why?
|
Inflammation | 10 | 2023 | 10860 | 0.440 |
Why?
|
Anti-Inflammatory Agents | 3 | 2018 | 1805 | 0.440 |
Why?
|
Atherosclerosis | 5 | 2023 | 3420 | 0.430 |
Why?
|
Anticholesteremic Agents | 2 | 2018 | 970 | 0.390 |
Why?
|
Cholesterol | 2 | 2023 | 2903 | 0.390 |
Why?
|
Insulin | 5 | 2024 | 6608 | 0.380 |
Why?
|
Interleukin-6 | 8 | 2018 | 3227 | 0.380 |
Why?
|
Lipoproteins, VLDL | 4 | 2021 | 198 | 0.380 |
Why?
|
Hyperinsulinism | 2 | 2006 | 402 | 0.370 |
Why?
|
Venous Thromboembolism | 3 | 2021 | 1882 | 0.370 |
Why?
|
Eicosapentaenoic Acid | 1 | 2015 | 565 | 0.370 |
Why?
|
Adiponectin | 2 | 2019 | 1121 | 0.360 |
Why?
|
Dyslipidemias | 1 | 2018 | 872 | 0.350 |
Why?
|
Coronary Artery Disease | 6 | 2023 | 6558 | 0.350 |
Why?
|
Risk Assessment | 19 | 2024 | 24295 | 0.330 |
Why?
|
Prospective Studies | 27 | 2023 | 54871 | 0.330 |
Why?
|
Diabetes Complications | 4 | 2011 | 1319 | 0.330 |
Why?
|
Risk Factors | 36 | 2023 | 74881 | 0.320 |
Why?
|
Docosahexaenoic Acids | 1 | 2015 | 915 | 0.300 |
Why?
|
Middle Aged | 54 | 2024 | 223257 | 0.290 |
Why?
|
Vitamin D | 2 | 2024 | 3270 | 0.280 |
Why?
|
Hypoglycemic Agents | 3 | 2017 | 3108 | 0.280 |
Why?
|
Metformin | 2 | 2017 | 908 | 0.280 |
Why?
|
Randomized Controlled Trials as Topic | 6 | 2021 | 10384 | 0.270 |
Why?
|
Coronary Disease | 5 | 2005 | 5915 | 0.270 |
Why?
|
Methotrexate | 3 | 2020 | 1719 | 0.270 |
Why?
|
Blood Glucose | 7 | 2024 | 6422 | 0.260 |
Why?
|
Aspirin | 4 | 2015 | 3135 | 0.250 |
Why?
|
Female | 59 | 2024 | 396520 | 0.240 |
Why?
|
Insulin Resistance | 7 | 2024 | 3989 | 0.240 |
Why?
|
Vitamin E | 3 | 2015 | 872 | 0.240 |
Why?
|
Arteriosclerosis | 3 | 2004 | 1055 | 0.230 |
Why?
|
Lipoprotein(a) | 3 | 2022 | 489 | 0.230 |
Why?
|
Humans | 76 | 2024 | 766766 | 0.220 |
Why?
|
Women's Health | 5 | 2015 | 2081 | 0.220 |
Why?
|
Dietary Supplements | 2 | 2024 | 3429 | 0.220 |
Why?
|
Fatty Acids, Omega-3 | 2 | 2024 | 1399 | 0.210 |
Why?
|
Case-Control Studies | 13 | 2021 | 22248 | 0.210 |
Why?
|
Proinsulin | 1 | 2003 | 135 | 0.210 |
Why?
|
C-Peptide | 1 | 2024 | 443 | 0.200 |
Why?
|
Sex Factors | 7 | 2021 | 10619 | 0.200 |
Why?
|
Obesity | 6 | 2019 | 13090 | 0.200 |
Why?
|
Double-Blind Method | 10 | 2024 | 12430 | 0.200 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2004 | 426 | 0.200 |
Why?
|
Apolipoproteins | 2 | 2021 | 328 | 0.200 |
Why?
|
Medicare | 1 | 2020 | 6820 | 0.190 |
Why?
|
Antihypertensive Agents | 1 | 2011 | 2030 | 0.190 |
Why?
|
Interleukin-1beta | 3 | 2018 | 1026 | 0.190 |
Why?
|
Chylomicron Remnants | 1 | 2021 | 3 | 0.190 |
Why?
|
Cholesterol, HDL | 4 | 2020 | 1812 | 0.190 |
Why?
|
Fibric Acids | 1 | 2021 | 27 | 0.180 |
Why?
|
Postmenopause | 3 | 2006 | 2517 | 0.180 |
Why?
|
Cohort Studies | 11 | 2020 | 41710 | 0.180 |
Why?
|
Follow-Up Studies | 13 | 2020 | 39309 | 0.170 |
Why?
|
Time Factors | 7 | 2024 | 40149 | 0.170 |
Why?
|
Proportional Hazards Models | 7 | 2020 | 12534 | 0.170 |
Why?
|
Colchicine | 1 | 2021 | 257 | 0.170 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 1 | 2002 | 692 | 0.170 |
Why?
|
Estrogen Replacement Therapy | 2 | 2005 | 1205 | 0.170 |
Why?
|
Tissue Plasminogen Activator | 2 | 2005 | 1164 | 0.160 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2023 | 3250 | 0.160 |
Why?
|
Lipoproteins, HDL | 3 | 2020 | 677 | 0.160 |
Why?
|
Smoking | 4 | 2015 | 9077 | 0.160 |
Why?
|
Drug Therapy, Combination | 5 | 2018 | 6307 | 0.160 |
Why?
|
Aged | 30 | 2024 | 171343 | 0.160 |
Why?
|
United States | 14 | 2021 | 72951 | 0.150 |
Why?
|
Hyperlipidemias | 1 | 2023 | 771 | 0.150 |
Why?
|
Disease Susceptibility | 2 | 2021 | 1791 | 0.140 |
Why?
|
Body Mass Index | 11 | 2020 | 13050 | 0.140 |
Why?
|
Calgranulin B | 2 | 2007 | 87 | 0.130 |
Why?
|
Adipose Tissue | 4 | 2019 | 3314 | 0.130 |
Why?
|
Blood Pressure | 2 | 2011 | 8533 | 0.130 |
Why?
|
Cerebrovascular Disorders | 1 | 2023 | 1479 | 0.130 |
Why?
|
Nuclear Magnetic Resonance, Biomolecular | 1 | 2018 | 502 | 0.130 |
Why?
|
Diabetes Mellitus | 4 | 2016 | 5887 | 0.130 |
Why?
|
Leptin | 2 | 2016 | 1596 | 0.130 |
Why?
|
Male | 29 | 2024 | 364142 | 0.120 |
Why?
|
Secondary Prevention | 1 | 2021 | 1469 | 0.120 |
Why?
|
Hypertension | 2 | 2011 | 8616 | 0.110 |
Why?
|
Acute-Phase Proteins | 1 | 2015 | 251 | 0.110 |
Why?
|
Diet, Mediterranean | 1 | 2020 | 746 | 0.110 |
Why?
|
Myocardial Infarction | 6 | 2018 | 11513 | 0.110 |
Why?
|
Fasting | 3 | 2006 | 1609 | 0.110 |
Why?
|
Predictive Value of Tests | 6 | 2015 | 15416 | 0.110 |
Why?
|
Lower Extremity | 1 | 2021 | 1217 | 0.100 |
Why?
|
Risk | 3 | 2013 | 9602 | 0.100 |
Why?
|
Molecular Weight | 2 | 2011 | 2168 | 0.100 |
Why?
|
Treatment Outcome | 7 | 2024 | 65273 | 0.100 |
Why?
|
Research Report | 1 | 2015 | 367 | 0.100 |
Why?
|
Heart Atria | 2 | 2008 | 1361 | 0.100 |
Why?
|
Atrial Natriuretic Factor | 1 | 2013 | 350 | 0.100 |
Why?
|
Lipids | 3 | 2019 | 3319 | 0.090 |
Why?
|
Statistics, Nonparametric | 3 | 2018 | 2846 | 0.090 |
Why?
|
Disease Management | 2 | 2020 | 2533 | 0.090 |
Why?
|
Fluorobenzenes | 1 | 2012 | 179 | 0.090 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2019 | 16044 | 0.090 |
Why?
|
Age Factors | 5 | 2021 | 18397 | 0.090 |
Why?
|
Placebos | 2 | 2020 | 1659 | 0.090 |
Why?
|
Antirheumatic Agents | 1 | 2020 | 1383 | 0.090 |
Why?
|
Body Weight | 4 | 2014 | 4626 | 0.080 |
Why?
|
Insulin, Long-Acting | 1 | 2009 | 59 | 0.080 |
Why?
|
Systole | 1 | 2011 | 935 | 0.080 |
Why?
|
Diastole | 1 | 2011 | 784 | 0.080 |
Why?
|
Drug Combinations | 1 | 2015 | 2085 | 0.080 |
Why?
|
Clinical Trials as Topic | 2 | 2023 | 8045 | 0.080 |
Why?
|
Immunoassay | 1 | 2012 | 742 | 0.080 |
Why?
|
Inpatients | 1 | 2020 | 2565 | 0.080 |
Why?
|
Polysaccharides | 1 | 2015 | 1020 | 0.080 |
Why?
|
Death, Sudden, Cardiac | 1 | 2016 | 1567 | 0.070 |
Why?
|
Estrogen Receptor beta | 1 | 2009 | 171 | 0.070 |
Why?
|
Life Style | 3 | 2014 | 3926 | 0.070 |
Why?
|
Receptors, Tumor Necrosis Factor, Type II | 1 | 2009 | 347 | 0.070 |
Why?
|
Calgranulin A | 1 | 2007 | 81 | 0.070 |
Why?
|
Antioxidants | 1 | 2015 | 1671 | 0.070 |
Why?
|
Chi-Square Distribution | 2 | 2011 | 3432 | 0.070 |
Why?
|
Echocardiography, Doppler | 2 | 2008 | 899 | 0.070 |
Why?
|
Neoplasms | 2 | 2015 | 22350 | 0.070 |
Why?
|
Forms and Records Control | 1 | 2007 | 158 | 0.070 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2012 | 4349 | 0.070 |
Why?
|
Platelet Aggregation Inhibitors | 2 | 2015 | 2763 | 0.070 |
Why?
|
Prognosis | 3 | 2021 | 29948 | 0.060 |
Why?
|
Anthropometry | 2 | 2008 | 1336 | 0.060 |
Why?
|
Immunosuppressive Agents | 1 | 2018 | 4215 | 0.060 |
Why?
|
Heptanoic Acids | 1 | 2007 | 344 | 0.060 |
Why?
|
Pravastatin | 1 | 2007 | 391 | 0.060 |
Why?
|
Cardiotonic Agents | 1 | 2008 | 541 | 0.060 |
Why?
|
Statistics as Topic | 1 | 2011 | 2351 | 0.060 |
Why?
|
Body Size | 1 | 2008 | 461 | 0.060 |
Why?
|
Logistic Models | 5 | 2016 | 13278 | 0.060 |
Why?
|
Estrogen Receptor alpha | 1 | 2009 | 581 | 0.060 |
Why?
|
Odds Ratio | 4 | 2007 | 9661 | 0.060 |
Why?
|
Atrial Fibrillation | 2 | 2014 | 5182 | 0.060 |
Why?
|
Waist-Hip Ratio | 1 | 2006 | 521 | 0.060 |
Why?
|
Fibrinogen | 1 | 2008 | 893 | 0.060 |
Why?
|
Interferon-gamma | 1 | 2012 | 3158 | 0.050 |
Why?
|
Confidence Intervals | 3 | 2018 | 2921 | 0.050 |
Why?
|
Reference Values | 4 | 2016 | 4913 | 0.050 |
Why?
|
Carotenoids | 1 | 2006 | 620 | 0.050 |
Why?
|
Lipoproteins, LDL | 2 | 2020 | 642 | 0.050 |
Why?
|
Patient Selection | 1 | 2015 | 4252 | 0.050 |
Why?
|
Analysis of Variance | 1 | 2011 | 6214 | 0.050 |
Why?
|
Social Class | 1 | 2011 | 2007 | 0.050 |
Why?
|
Diet | 3 | 2020 | 8088 | 0.050 |
Why?
|
Sulfonamides | 1 | 2012 | 1982 | 0.050 |
Why?
|
Genetic Predisposition to Disease | 3 | 2021 | 18075 | 0.050 |
Why?
|
Diabetic Angiopathies | 1 | 2007 | 806 | 0.050 |
Why?
|
Endocarditis, Bacterial | 1 | 2006 | 436 | 0.050 |
Why?
|
Creatinine | 1 | 2008 | 1917 | 0.050 |
Why?
|
Lovastatin | 1 | 2002 | 114 | 0.050 |
Why?
|
Multivariate Analysis | 2 | 2008 | 12064 | 0.050 |
Why?
|
Pyrroles | 1 | 2007 | 1121 | 0.050 |
Why?
|
Antibodies, Monoclonal | 1 | 2018 | 9244 | 0.050 |
Why?
|
Primary Prevention | 1 | 2008 | 1188 | 0.050 |
Why?
|
Genome-Wide Association Study | 2 | 2021 | 12806 | 0.040 |
Why?
|
Solubility | 1 | 2002 | 1078 | 0.040 |
Why?
|
Comorbidity | 2 | 2007 | 10580 | 0.040 |
Why?
|
Adult | 11 | 2021 | 223307 | 0.040 |
Why?
|
Hospitalization | 1 | 2020 | 10823 | 0.040 |
Why?
|
Pyrimidines | 1 | 2012 | 3043 | 0.040 |
Why?
|
Apolipoprotein B-100 | 1 | 2020 | 157 | 0.040 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2010 | 3681 | 0.040 |
Why?
|
Aged, 80 and over | 5 | 2019 | 59550 | 0.040 |
Why?
|
Migraine Disorders | 1 | 2012 | 1710 | 0.040 |
Why?
|
Gene Expression Regulation | 2 | 2016 | 11920 | 0.040 |
Why?
|
Premedication | 1 | 2020 | 245 | 0.040 |
Why?
|
Smoking Cessation | 1 | 2011 | 2085 | 0.040 |
Why?
|
Apolipoprotein A-I | 1 | 2020 | 305 | 0.040 |
Why?
|
Longitudinal Studies | 2 | 2015 | 14762 | 0.040 |
Why?
|
Antigens | 1 | 2004 | 1441 | 0.040 |
Why?
|
Glucose Intolerance | 1 | 2002 | 578 | 0.040 |
Why?
|
Quantitative Trait, Heritable | 1 | 2021 | 541 | 0.040 |
Why?
|
Patient Compliance | 1 | 2008 | 2694 | 0.040 |
Why?
|
Amino Acids, Branched-Chain | 1 | 2020 | 267 | 0.040 |
Why?
|
Transaminases | 1 | 2018 | 198 | 0.040 |
Why?
|
Gene Expression Profiling | 2 | 2021 | 9525 | 0.040 |
Why?
|
Abdomen | 1 | 2003 | 1137 | 0.040 |
Why?
|
Hormone Replacement Therapy | 1 | 2003 | 751 | 0.040 |
Why?
|
Policy | 1 | 2021 | 512 | 0.030 |
Why?
|
RNA, Messenger | 2 | 2016 | 12791 | 0.030 |
Why?
|
Islets of Langerhans | 1 | 2003 | 1350 | 0.030 |
Why?
|
American Heart Association | 1 | 2021 | 1049 | 0.030 |
Why?
|
Sensitivity and Specificity | 1 | 2011 | 14652 | 0.030 |
Why?
|
Weight Gain | 1 | 2006 | 2356 | 0.030 |
Why?
|
Blood Platelets | 1 | 2006 | 2465 | 0.030 |
Why?
|
Echocardiography | 1 | 2008 | 5037 | 0.030 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2006 | 2143 | 0.030 |
Why?
|
Congresses as Topic | 1 | 2020 | 811 | 0.030 |
Why?
|
Tissue Culture Techniques | 1 | 2016 | 287 | 0.030 |
Why?
|
Menopause | 1 | 2003 | 1657 | 0.030 |
Why?
|
Acute Coronary Syndrome | 1 | 2007 | 2186 | 0.030 |
Why?
|
Regression Analysis | 1 | 2003 | 6329 | 0.030 |
Why?
|
Homeostasis | 1 | 2024 | 3342 | 0.030 |
Why?
|
Lipid Metabolism | 1 | 2021 | 1895 | 0.030 |
Why?
|
Probability | 2 | 2008 | 2476 | 0.030 |
Why?
|
Prediabetic State | 1 | 2018 | 547 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2006 | 7841 | 0.020 |
Why?
|
Body Height | 2 | 2008 | 1562 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2016 | 1604 | 0.020 |
Why?
|
Quantitative Trait Loci | 1 | 2019 | 2136 | 0.020 |
Why?
|
Adiposity | 1 | 2020 | 1892 | 0.020 |
Why?
|
Lipoproteins, IDL | 1 | 2010 | 18 | 0.020 |
Why?
|
Thrombosis | 1 | 2004 | 2953 | 0.020 |
Why?
|
Alleles | 1 | 2021 | 6895 | 0.020 |
Why?
|
Inflammation Mediators | 2 | 2011 | 1889 | 0.020 |
Why?
|
Alcohol Drinking | 1 | 2003 | 4045 | 0.020 |
Why?
|
Sweetening Agents | 1 | 2012 | 291 | 0.020 |
Why?
|
Stroke | 2 | 2018 | 9741 | 0.020 |
Why?
|
Exercise | 1 | 2006 | 5945 | 0.020 |
Why?
|
Cross-Sectional Studies | 3 | 2005 | 26310 | 0.020 |
Why?
|
Body Surface Area | 1 | 2008 | 206 | 0.020 |
Why?
|
Vitamins | 1 | 2015 | 1631 | 0.020 |
Why?
|
Health Care Costs | 1 | 2020 | 3242 | 0.020 |
Why?
|
Beverages | 1 | 2012 | 819 | 0.020 |
Why?
|
Xanthophylls | 1 | 2006 | 95 | 0.020 |
Why?
|
Lutein | 1 | 2006 | 123 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2018 | 10745 | 0.020 |
Why?
|
Colorectal Neoplasms | 1 | 2005 | 6962 | 0.020 |
Why?
|
Disease Progression | 1 | 2002 | 13640 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 3804 | 0.010 |
Why?
|
beta Carotene | 1 | 2006 | 523 | 0.010 |
Why?
|
Bundle-Branch Block | 1 | 2006 | 280 | 0.010 |
Why?
|
Reference Standards | 1 | 2008 | 1010 | 0.010 |
Why?
|
Educational Status | 1 | 2011 | 2510 | 0.010 |
Why?
|
Antigens, Differentiation, T-Lymphocyte | 1 | 2006 | 897 | 0.010 |
Why?
|
Acute Disease | 2 | 2006 | 7241 | 0.010 |
Why?
|
Adolescent | 4 | 2019 | 88904 | 0.010 |
Why?
|
Income | 1 | 2011 | 1875 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2020 | 7431 | 0.010 |
Why?
|
Lectins, C-Type | 1 | 2006 | 592 | 0.010 |
Why?
|
Haplotypes | 1 | 2009 | 2727 | 0.010 |
Why?
|
Myocardium | 1 | 2015 | 4765 | 0.010 |
Why?
|
Massachusetts | 1 | 2015 | 8891 | 0.010 |
Why?
|
Hemostasis | 1 | 2005 | 467 | 0.010 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2006 | 678 | 0.010 |
Why?
|
Stroke Volume | 2 | 2006 | 5618 | 0.010 |
Why?
|
Gene Frequency | 1 | 2009 | 3624 | 0.010 |
Why?
|
Megakaryocytes | 1 | 2006 | 557 | 0.010 |
Why?
|
Random Allocation | 1 | 2006 | 2394 | 0.010 |
Why?
|
International Classification of Diseases | 1 | 2007 | 935 | 0.010 |
Why?
|
Phenotype | 1 | 2019 | 16724 | 0.010 |
Why?
|
Pacemaker, Artificial | 1 | 2006 | 828 | 0.010 |
Why?
|
Anti-Infective Agents | 1 | 2007 | 987 | 0.010 |
Why?
|
Doxorubicin | 1 | 2006 | 2229 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 4570 | 0.010 |
Why?
|
Thrombolytic Therapy | 1 | 2007 | 2053 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2016 | 15908 | 0.010 |
Why?
|
Staphylococcal Infections | 1 | 2006 | 1396 | 0.010 |
Why?
|
Research Design | 1 | 2013 | 6207 | 0.010 |
Why?
|
Antigens, CD | 1 | 2006 | 4032 | 0.010 |
Why?
|
Prevalence | 1 | 2012 | 15835 | 0.010 |
Why?
|
Mice | 2 | 2016 | 81889 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2012 | 20144 | 0.010 |
Why?
|
Animals | 3 | 2016 | 168930 | 0.010 |
Why?
|
Linear Models | 1 | 2003 | 5874 | 0.010 |
Why?
|
Ventricular Function, Left | 1 | 2006 | 3935 | 0.010 |
Why?
|
Survival Rate | 1 | 2007 | 12825 | 0.010 |
Why?
|
Electrocardiography | 1 | 2006 | 6408 | 0.010 |
Why?
|
Algorithms | 1 | 2013 | 14072 | 0.010 |
Why?
|
Young Adult | 1 | 2019 | 59939 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 2006 | 7609 | 0.010 |
Why?
|
Apoptosis | 1 | 2006 | 9513 | 0.010 |
Why?
|
Child | 2 | 2008 | 80668 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2006 | 22352 | 0.000 |
Why?
|
Infant | 1 | 2008 | 36461 | 0.000 |
Why?
|
Child, Preschool | 1 | 2008 | 42577 | 0.000 |
Why?
|
Retrospective Studies | 1 | 2008 | 81635 | 0.000 |
Why?
|